share_log

Needham Maintains Buy on Blueprint Medicines, Raises Price Target to $133

Needham Maintains Buy on Blueprint Medicines, Raises Price Target to $133

Needham维持Blueprint Medicines的买入评级,将价格目标上调至133美元。
Benzinga ·  08/05 15:13  · 评级/大行评级

Needham analyst Ami Fadia maintains Blueprint Medicines (NASDAQ:BPMC) with a Buy and raises the price target from $130 to $133.

Needham分析师 Ami Fadia 维持对blueprint medicines(纳斯达克代码:BPMC)的买入评级,将目标股价从130美元上调至133美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发